Healthcare Analyst Fadia, along with Specialty Pharma Expert Kevin O’Keeffe, discuss factors to consider in estimating the number of patients that will eventually get AVDL‘s Lumryz based on enrollment in the RYZUP patient support services hub on an Analyst/Industry conference call to be held on October 3 at 11 am.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVDL:
- Needham healthcare analyst to hold an analyst/industry conference call
- Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
- Avadel Pharmaceuticals price target raised to $18 from $13 at Piper Sandler
- Avadel Pharmaceuticals reports Q2 EPS (83c), consensus (38c)
- Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results